CATEGORIES

Healthcare

LATEST

TRENDING

EDITORS CHOICE

First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial

The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and F3 NASH patients

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia

Alterity and UniQuest Partner to Reverse Bacterial Resistance to Antibiotics

Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics

HIMSS – Global Meeting Ground for Health Info Innovators to Secure Partnerships and Advance Care

10 Israeli Innovators Head Toward Orlando with New Approaches to Hospital Efficiency and Improved Patient Care - Showing Engineering Marvel and AI Potential